In a HNSCC heterotopic xenograft tumor model, treatment with the epidermal growth factor receptor (EGFR) blocker Cetuximab inhibits angiogenesis by downregulating Notch1 and Hypoxia-inducible factor 1 alpha (Hif1α) subunit [83]. Here, HIF1A is linked to neoplasm.